ClinicalTrials.gg
RecruitingNCT06870981Opti-NuMUpdated Mar 11, 2025

Optimizing Nutrition and Milk (Opti-NuM) Project

An observational study in Very Low Birth Weight Baby, Early Nutrition and the Preterm Infant and Nutritional Requirements, sponsored by The Hospital for Sick Children. Recruiting at 6 sites in 2 countries. Open to participants aged 1 Hour to 21 Days. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by The Hospital for Sick Children · Observational

How we know

From the registry’s dates

  • Started Oct 2010; still recruiting 16 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,100
Ages
1 Hour to 21 Days
Sex
All
01

Study summary

Early nutrition critically influences growth, neurodevelopment and morbidity among infants born of very low birth weight (VLBW), but current one-size-fits-all feeding regimes do not optimally support these vulnerable infants. There is increasing interest in "precision nutrition" approaches, but it is unclear which Human Milk (HM) components require personalized adjustment of doses. Previous efforts have focused on macronutrients, but HM also contains essential micronutrients as well as non-nutrient bioactive components that shape the gut microbiome. Further, it is unclear if or how parental factors (e.g. body mass index, diet) and infant factors (e.g. genetics, gut microbiota, sex, acuity) influence relationships between early nutrition and growth, neurodevelopment and morbidity. Understanding these complex relationships is paramount to developing effective personalized HM feeding strategies for VLBW infants. This is the overarching goal of the proposed Optimizing Nutrition and Milk (Opti-NuM) Project.

The Opti-NuM Project brings together two established research platforms with complementary expertise and resources: 1) the MaxiMoM Program* with its clinically embedded translational neonatal feeding trial network in Toronto (Dr. Deborah O'Connor, Dr. Sharon Unger) and 2) the International Milk Composition (IMiC) Consortium, a world-renowned multidisciplinary network of HM researchers and data scientists collaborating to understand how the myriad of HM components contribute "as a whole" to infant growth and development, using systems biology and machine learning approaches. Members of the IMiC Corsortium that will work with on this study are located at the University of Manitoba (Dr. Meghan Azad), University of California (Dr. Lars Bode) and Stanford (Dr. Nima Aghaeepour).

Read the detailed description

Observational study mode:

The Opti-NuM Project is a retrospective secondary data/sample use study.

Time perspective:

Secondary use data and biospecimens accruing from the 2 completed studies DoMINO and OptiMOM (NCT02137473) and 1 ongoing RCT MaxiMoM (NCT05308134) are included in this project.

Sampling method:

This project is a secondary use of data/samples, from a cohort consisting of participants of the MaxiMoM Platform RCTs.

02

Conditions studied

  • Very Low Birth Weight Baby
  • Early Nutrition and the Preterm Infant
  • Nutritional Requirements
  • Human Milk Fortification
  • Human Milk Microbiome
  • Human Milk Feeding
  • Human Milk Nutrition
  • Growth &Amp; Development

Browse trials for

Keywords

  • Very Low Birth Weight Infants
  • Early nutrition and the preterm infant
  • Human milk feeding
03

In context

Birth Weight

185 studies on the registry are indexed under Birth Weight; 24 are open to participants now.

This study's planned enrollment of 1,100 is above the median of 240 across 63 observational studies indexed under Birth Weight.

Browse Birth Weight studies →

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Hour to 21 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Very Low Birth Weight infants

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Secondary data and biospecimens from participants of the MaxiMoM Platform RCTs

Exclusion criteria

Exclusion Criteria:

  • Data and biospecimens from infants who are not enrolled in the three trials are eligible for this project.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants of the MaxiMoM Platform Trials

    Secondary data use and biospecimens from participants of the MaxiMoM Platform Trials are infants born 1500g or less (infant weight), born in the Greater Toronto Area.

    Other: Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study.

Interventions

  • OtherOpti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study.
06

What researchers measure

Primary outcomes

  1. Cognitive composite score on the Bayley Scales of Infant and Toddler Development.

    Our primary outcome is the cognitive composite score on the Bayley Scales of Infant and Toddler Development collected from the medical record or by home-visit by our research staff. The Bayley is the most widely used instrument globally by clinicians and researchers to assess developmental functioning of infants, toddlers and young children across cognitive, language (receptive, expressive) and motor (fine, gross) domains. Cognitive, language and motor composite scores will be standardized to a mean of 100 with a standard deviation of 15. The range on the composite Bayle Scores is from less than 0.1 to more than 99.9 percentile. A score lower than the 10th percentile indicates developmental delay.

    Time frame: At 18-24 months CA

Secondary outcomes

  1. Language composite score from the Bayley Scales of Infant and Toddler Development

    Language composite score from the Bayley Scales of Infant and Toddler Development. The range on the composite Bayle Scores is from less than 0.1 to more than 99.9 percentile. A score lower than the 10th percentile indicates developmental delay.

    Time frame: At 18-24 months CA

  2. Motor composite score from the Bayley Scales of Infant and Toddler Development

    Motor composite score from the Bayley Scales of Infant and Toddler Development. The range on the composite Bayle Scores is from less than 0.1 to more than 99.9 percentile. A score lower than the 10th percentile indicates developmental delay.

    Time frame: At 18-24 months CA

  3. Weight (g)

    Weight gains serve as early indicators of the effectiveness of early nutrition and are on the causal pathway to neurodevelopment. Daily weights are prospectively extracted from medical records.

    Time frame: Initial hospitalization, approximately 50 days; at 4 months and 18-24 months CA clinic visit.

  4. Length (cm)

    Length gains serve as early indicators of the effectiveness of early nutrition and are on the causal pathway to neurodevelopment. Weekly length is determined by research staff using length boards and standardized procedures.

    Time frame: Initial hospitalization, approximately 50 days; at 4 months and 18-24 months CA clinic visit.

  5. Head circumference (cm)

    Head circumference (HC) gains serve as early indicators of the effectiveness of early nutrition and are on the causal pathway to neurodevelopment. Weekly HC measurements are determined by research staff using non-stretchable tape measures and standardized procedures.

    Time frame: Initial hospitalization, approximately 50 days; at 4 months and 18-24 months CA clinic visit.

  6. Serious morbidities

    Serious morbidities including late-onset sepsis (\>day 5, positive blood or cerebrospinal fluid culture), NEC (Bell stage ≥II), chronic lung disease (respiratory support at 36 weeks) and retinopathy of prematurity requiring treatment are collected prospectively from the medical chart.

    Time frame: During hospital stay, an average of 60 days.

07

Study locations

2 of 6 sites recruiting
08

References and documents

Publications

  • O'Connor DL, Kiss A, Tomlinson C, Bando N, Bayliss A, Campbell DM, Daneman A, Francis J, Kotsopoulos K, Shah PS, Vaz S, Williams B, Unger S; OptiMoM Feeding Group. Nutrient enrichment of human milk with human and bovine milk-based fortifiers for infants born weighing <1250 g: a randomized clinical trial. Am J Clin Nutr. 2018 Jul 1;108(1):108-116. doi: 10.1093/ajcn/nqy067. PubMed 29878061 ↗
  • O'Connor DL, Gibbins S, Kiss A, Bando N, Brennan-Donnan J, Ng E, Campbell DM, Vaz S, Fusch C, Asztalos E, Church P, Kelly E, Ly L, Daneman A, Unger S; GTA DoMINO Feeding Group. Effect of Supplemental Donor Human Milk Compared With Preterm Formula on Neurodevelopment of Very Low-Birth-Weight Infants at 18 Months: A Randomized Clinical Trial. JAMA. 2016 Nov 8;316(18):1897-1905. doi: 10.1001/jama.2016.16144. PubMed 27825008 ↗

Individual participant data

Plan to share: Yes — Data transfer will take place via Secure File Transfer Protocol (SFTP). Sub-agreements which cover data and sample sharing and confidentiality is in place.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: December 2024 to December 2027

Access criteria: During the Opti-NuM project the following institutions will be involved in data and sample analysis as indicated. Data sharing will take place through SFTP, bio specimens will be shipped for analyses. The Hospital for Sick Children (Lead, Deborah O'Connor PhD RD): Both data and sample analysis The University of Toronto (Lead, Deborah O'Connor PhD RD): Both data and sample analysis The University of Manitoba (Lead, Meghan Azad PhD): Data analysis; No sample analysis Stanford University (Lead, Nima Aghaeepour PhD): Data analysis; No sample analysis University of California (Lead, Lars Bode PhD): Oligosaccharide analysis of human milk samples only. No data provided to this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2010 (actual). Primary completion is estimated for Dec 2026, 194 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Mar 11, 2025
StartActual
Oct 1, 2010
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06870981
Responsible party
Deborah O'Connor (Senior Associate Scientist, The Hospital for Sick Children) — Principal investigator
First posted
Mar 11, 2025
Start date
Oct 1, 2010
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 11, 2025

Study contacts

Dubraiicka Pichardo, MSc
Contact
dubraiicka.pichardo@sickkids.ca
416-813-7654 ext. 305777
Aneta Plaga, BSc
Contact
aneta.plaga@utoronto.ca
416-978-2422
Deborah L O'Connor, PhD, RN
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion